What Immcell Ltd does

Immcell Limited is an Ireland-based, family-owned B2B ingredient and pharmaceutical technology company operating within the Immdal Group, headquartered in Swords, Co. Dublin. The company develops and licenses plant-based functional food ingredients and pharmaceutical technology solutions through two operating divisions: Immcell Nutra, which supplies functional food ingredients such as Rapeseed Protein (a PDCAAS-1 plant protein derived from rapeseed meal, a by-product of cold press oil extraction) and B-NUC™ (a trademarked high-purity beta polymorph of inosine positioned for immune system modulation); and Immcell Pharma, which is developing a Natural Biofilm Inhibitor in collaboration with Technological University Dublin, targeting biofilm prevention and disruption across food manufacturing and healthcare applications.

The underlying technology relies on proprietary natural-compound formulations, GMP manufacturing standards, and academic co-development rather than in-house AI-driven discovery. Products are positioned for integration into B2B partners' own brands and formulations, with applications spanning nutritional bars, supplements, sports nutrition, infant nutrition, dairy-free products, bakery, capsules, beverages, medical devices, and food preservation. Manufacturing is conducted to GMP standards and is accompanied by a consolidated clinical development network for the pharmaceutical product line.

Immcell monetizes primarily through B2B licensing and distribution agreements with food and pharmaceutical industry partners, complemented by direct R&D sample sales (for example, Rapeseed Protein priced at €30 per 10 grams) via an online shop to facilitate partner evaluation. Go-to-market is sales-led, conducted through the corporate website, newsletter, and direct contact (phone and email), with no consumer-facing retail channel. The company's stated target markets are global, although its identified served geography is currently EMEA, and no customer logos, revenue figures, or funding rounds are publicly disclosed.

Name

Immcell Ltd

Legal name

Immcell Limited

Website

https://immcell.ie

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Immcell Limited is an Ireland-based, family-owned B2B company within the Immdal Group that develops and licenses plant-based functional food ingredients and pharmaceutical technology solutions, including Rapeseed Protein, B-NUC™ Beta Inosine, and a Natural Biofilm Inhibitor, to food and pharmaceutical industry partners.

Ownership category

akta.pro rank

Product category

Plant-based Nutraceutical Ingredients

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833), Miscellaneous Food Preparations & Kindred Products (2090)

akta.pro primary industry

Fortification Ingredients (Vitamins, Minerals, Nutrient Premixes) (CRADAOAM)

akta.pro secondary industries

Preservatives & Antimicrobials (Sorbates, Benzoates, Natamycin, Cultured Dextrose) (CRADAOAF), Foods for Special Dietary Needs Manufacturing (Gluten-Free, Allergen-Free, Low-FODMAP, Low-Sodium) (AFAKAJAD)

Keywords

• Plant-based protein ingredients
• Functional food ingredients
• Nutraceutical ingredients
• Pharmaceutical technology licensing
• Anti-biofilm technology

Headquarters

HQ city

Swords

HQ country

Ireland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. B2B Product Licensing: Licensing innovative plant-based technologies and ingredients to B2B partners in the food and pharmaceutical industries for integration into their product formulations and brands.
2. Sample Product Sales: Direct sales of product samples (Rapeseed Protein at €30.00 for 10 grams) for R&D purposes to potential B2B partners evaluating ingredients for incorporation into their products.
3. Technology Solutions Licensing: Licensing of pharmaceutical technology solutions including the Natural Biofilm Inhibitor technology to healthcare and pharmaceutical companies.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Immcell develops and supplies proprietary plant-based nutraceutical ingredients and pharmaceutical technology solutions to B2B customers in the food and pharmaceutical industries. Its commercial portfolio centers on Rapeseed Protein (a plant-based protein from rapeseed meal), B-NUC™ Beta Inosine (an immune-modulating functional ingredient), and the Natural Biofilm Inhibitor (anti-biofilm technology developed with Technological University Dublin), all manufactured to GMP standards and delivered primarily via licensing and ingredient supply partnerships.

Product overview

Immcell operates through two main divisions: Immcell Nutra and Immcell Pharma. Immcell Nutra offers functional food ingredients including Rapeseed Protein (plant-based protein with complete amino acid profile for nutritional applications) and B-NUC™ (Beta Inosine), an immune-modulating functional ingredient. Immcell Pharma focuses on technology-based pharmaceutical solutions, including the Natural Biofilm Inhibitor developed in collaboration with Technological University Dublin. The company manufactures products to GMP standards for B2B distribution and licensing.

Differentiator

Problem solved

Functional benefit

Brands

• B-NUC™ (Beta Inosine): Innovative functional food ingredient - a high purity beta polymorph of inosine that modulates the immune system.
• Rapeseed Protein
• Natural Biofilm Inhibitor

Products and services

• Rapeseed Protein (RSP) Plant-based protein ingredient produced from rapeseed meal (a by-product of cold press rapeseed oil extraction), with a complete essential amino acid profile, non-GMO and Irish-sourced credentials, dairy and lactose free, and a PDCAAS-1 rating. Designed for B2B integration into nutritional bars, supplements, sports nutrition, infant nutrition, dairy-free products, and bakery products by food and beverage manufacturers.
• B-NUC™ (Beta Inosine) Trademarked high-purity beta polymorph of inosine developed by Immcell as a functional food ingredient that modulates the immune system, supporting innate and adaptive immunity, cognition, energy generation, nerve cell and brain health, and heart health. Suitable for capsules, gels, bars, protein powders, yoghurts, beverages, and smoothies across all age groups, with particular relevance for the ageing population; offered for B2B licensing and supply.
• Natural Biofilm Inhibitor Anti-biofilm pharmaceutical technology developed with Technological University Dublin (TUD) that investigates anti-biofilm activity of specific compounds, targeting both prevention of biofilm formation and post-formation disruption. Intended for B2B licensing to medical device manufacturers (catheters, prosthetics), food and beverage manufacturing plants, and fruit and vegetable preservation applications in the pharmaceutical and healthcare sectors.

Quantifiable outcome

• Plant-based food sales grew 5 times faster than overall retail food sales (11% v 2%)
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Technological University Dublin (TUD)coreStrategic or Co-development PartnerOngoing research collaboration investigating anti-biofilm activity of specific compounds within the food category. In-depth investigation is ongoing to determine anti-biofilm properties against various micro-organisms problematic in food and healthcare industries. Studies focused on both prevention of biofilm formation and post-formation disruption.
• Immdal GroupcoreOthersImmcell is a family-owned nutraceutical company that forms an integral part of the Immdal Group, with innovation at the heart of all operations and focus on new-to-world plant-based technologies.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Ingredion: Global ingredient solutions provider with plant-based proteins and specialty starches. Comparable B2B ingredient licensing/supply model serving food and beverage manufacturers.
• Glanbia Nutritionals: Irish-headquartered global nutrition and ingredient company with plant-based protein and premix offerings. Comparable Irish B2B ingredient model serving food and supplement manufacturers.
• Roquette: Global leader in plant-based ingredients including pea protein (NUTRALYS) and other specialty proteins. Operates at vastly larger scale but addresses the same B2B functional protein market as Immcell.
• Kerry Group: Irish-headquartered B2B food ingredients and taste solutions giant. Strong geographic and customer overlap with Immcell's food industry focus, but at much larger scale across broader ingredient categories.
• ADM (Archer Daniels Midland): Global nutrition and agricultural processor with substantial plant protein ingredient business. Major potential competitor and/or licensing partner for functional food ingredients.
• Cargill: Global agribusiness with extensive plant protein ingredient portfolio (e.g., Puris pea protein). Competes for the same B2B protein customers with vastly greater scale and R&D resources.

Direct peers

• Burcon NutraScience: Canadian plant protein ingredient company that has developed canola/rapeseed proteins (Puratein, Supertein). Directly comparable to Immcell's rapeseed protein ingredient business in both feedstock and target B2B customers.
• AGT Food and Ingredients: Global supplier of pulse and plant protein ingredients to food manufacturers. Comparable B2B plant-protein ingredient model with similar customer base of food and beverage formulators.

Emerging players

• Kane Biotech: Canadian biotech developing anti-biofilm technologies for human and animal health applications. Directly comparable to Immcell's Natural Biofilm Inhibitor program in technology and end markets.
• BioFilm Control: French biotech focused on anti-biofilm enzyme-based solutions for healthcare and food safety. Closest emerging technology peer to Immcell's biofilm-disruption approach.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/immcell

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immcell Ltd